Exenatide
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
AstraZeneca · Phase 3 · Status n/r · Enrollment 150
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Liraglutide | n/r | n/r | n/r | n/r |
| Exenatide | n/r | n/r | n/r | n/r |
| Exenatide Microspheres for Injection | n/r | n/r | n/r | n/r |
Not shown
- Liraglutide: endpoint not reported
- Exenatide: endpoint not reported
- Exenatide Microspheres for Injection: endpoint not reported